Optimize Outcomes and Health Economic Research with TreeAge Pro Software
Over the recent years, the ever changing market dynamics of the pharmaceutical industry has placed considerable emphasis on demonstrating a product's overall value — versus issues of efficacy, safety and acquisition costs. This trend is influencing pharmaceutical companies to pay more attention to patient reported outcomes and pharmacoeconomic data to establish the help overall value of their products. TreeAge Pro Suite provides model building and analysis tools to assist outcomes researchers and health economists use pharmacoeconomic data to quantify the economic impact of new treatments and overall treatment costs. By establishing a clear and understandable value proposition for a new treatment or drug, pharmaceutical companies increase their opportunity for access to formulary placement and greater revenues.

TreeAge Pro Suite can help you present options, specify risks and analyze the effects of uncertainty - particularly when it is important to consider both the costs of available strategies and the value placed on particular health outcomes.

In an era of limited resources and growing demands on pharmaceutical companies, many health researchers and pharmacoeconomists are using TreeAge software to demonstrate cost-effectiveness and establish a better value proposition. In addition, TreeAge Pro Suite allows you to model treatment protocols, immunization programs, diagnostic testing and pharmaceutical R&D projects and then analyze these complex decisions on the basis of a single criterion (e.g., life expectancy or patient utility) or multiple criteria (e.g., cost-effectiveness or cost-utility).

TreeAge Pro Healthcare Offers Cost-Effectiveness Analysis … And More
TreeAge Pro Healthcare lets you analyze models on the basis of expected costs, expected effectiveness or combined cost-effectiveness, and automatically generates graphs and reports including marginal cost, marginal effectiveness and marginal cost-effectiveness information. Instances of absolute or extended dominance (including parameters) are identified both graphically and in text reports. Powerful sensitivity analysis can be carried out in cost-effectiveness models.

To go beyond expected value information, TreeAge Pro Healthcare offers extensive Monte Carlo simulation capabilities. Markov processes are graphically displayed with nodes to identify all of the potential states and the potential state transitions. The software also includes tunnel states and the ability to define tables which specify state transition probabilities for any stage during the Markov model analysis.

Other features of particular interest to the pharmaceutical communities include:

• Built-in Markov analysis-related functions such as declining exponential approximation of life expectancy ("DEALE")
• Conversion of mortality rates into probability of death
• Discounted utilities, and many parameterized distributions
• Implementation of Bayes' revision to convert test/procedure sensitivity and specificity values into meaningful decision probabilities
• A table interface allowing the entry of mortality or other Markov analysis-related tables for use in any number of trees

Achieve Greater Return on Iinvestment from your Outcomes Research Efforts by Using
TreeAge Pro Suite
When it comes to demonstrating a product's value in terms of cost and quality of life, TreeAge Software has been providing the pharmaceutical industry with the industry standard model building and analysis tools for years. Our latest release, "TreeAge Pro Suite" provides the most advanced and comprehensive set of decision analysis tools for the pharmaceutical industry, including tools and features that assist outcomes research groups in the following areas:

EARLY STAGE OUTCOMES RESEARCH

• Conduct economic and outcomes studies that profile trends in care delivery.
• Quantify the value of medical technologies and innovations.
• Design cost-of-illness studies.
• Assess market opportunities for new therapies.
• Evaluate alternative treatment decision pathways.
• Develop economic models.

LATER STAGE OUTCOMES RESEARCH

• Assess the impact of new medical innovations and therapies.
• Analyze the economic, quality-of-life, resource utilization, or caregiver-related outcomes of drug therapies.

PHARMAECONOMIC MODELING

• Evaluate healthcare policy and coverage decisions.
• Demonstrate the cost-effectiveness and clinical utility of new technologies.
• Share and communicate cost-effectiveness data to third party payers.
• Develop meaningful decision-analysis models displaying the impact of various treatment pathways.
• Demonstrate real world outcomes of new products after they have been launched.
• Conduct micro and macro costing analyses.
• Perform all types of pharmacoeconomic analyses.

Join the many other pharmaceutical companies and health economists who have been using TreeAge software to support their outcomes research efforts.

See how Johnson & Johnson uses TreeAge software to facilitate outcomes based research within their company:

George Papadopoulos, Director of Health Economics and Pricing at Johnson & Johnson Pharmaceutical Services, uses TreeAge Pro Healthcare's cost-effectiveness features to demonstrate the value of new pharmaceutical products and set pricing.
Learn more about how Johnson & Johnson's strategic marketing group uses TreeAge software. >

 

Learn more about TreeAge Pro Healthcare. >
Learn more about the TreeAge Pro Suite. >